New York, NY · Founded 2021 · Privately Held (backing)
Developer of first-in-class genomic medicines designed for renal indications, combining the promise of non-viral targeted delivery and genome editing for the kidney. Helex is based in New York, NY and was founded in 2021. Its last reported valuation was $36.9 million in Oct 2025. It has raised $6.6 million.
Last reported valuation
$36.9M
Oct 2026
Priced at
—
Total raised
$6.6M
Last round
—
Cap table — not yet on record
Helex's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Helex with a free account
·Watch Helex: the Monday email on marks, rounds and moves
